Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0310)
Name
Nutlin-3
Synonyms
Nutlin-3; 548472-68-0; 890090-75-2; nutlin 3; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; (Rac)-Nutlin-3; (+/-)-Nutlin3; 4-[[4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one; CHEMBL211045; (+)-Nutlin-3; (?)-Nutlin-3; MFCD14636430; Nutlin 3(Random Configuration); Nutlin3; NSC-732664; Rac-Nutlin-3; Nutln 3A; MFCD07784509; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; the p53/MDM2 Agonist; SCHEMBL2458627; BDBM31197; CHEBI:93777; EX-A851; HMS3651G03; HMS3653F08; HMS3653J08; HMS3750A11; AMY39899; BCP02265; BCP05161; BCP29278; MFCD11977784; NSC732664; s1061; AKOS005146527; CCG-264800; SB19406; SB19407; NCGC00165848-01; NCGC00165848-02; AC-35939; AS-10121; SY283510; SY289992; FT-0700329; FT-0713388; FT-0771774; FT-0773561; SW220144-1; H10266; A861337; J-514247; J-523776; BRD-A12230535-001-01-8; Q27165473; Z2159890360; (+-)-4-[4,5-dihydro-imidazole-1-carbonyl]piperazin-2-one; (-)-4-(4,5-bis-(4-Chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazole-1-carbonyl)piperazine-2-one; (??)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one; 4-{[(4S,5R)-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazol-1-yl]carbonyl}-2-piperazinone; RG7112;R7112;rel-4-((4R,5S)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one

    Click to Show/Hide
Structure
Formula
C30H30Cl2N4O4
IUPAC Name
4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
Canonical SMILES
CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl
InChI
InChI=1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)
InChIKey
BDUHCSBCVGXTJM-UHFFFAOYSA-N
PubChem CID
216345
Full List of Ferroptosis Target Related to This Drug
Ferroptosis suppressor protein 1 (AIFM2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Colon cancer ICD-11: 2B90
 Disease Info 
Responsed Regulator E3 ubiquitin-protein ligase Mdm2 (MDM2) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model HCT 116 cells Colon carcinoma Homo sapiens CVCL_0291
NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
SK-HEP-1 cells Liver and intrahepatic bile duct epithelial neoplasm Homo sapiens CVCL_0525
HT-1080 cells Fibrosarcoma Homo sapiens CVCL_0317
Response regulation Inhibition of MDM2 (Nutlin-3) or MDMX (NCS207895) leads to increased levels of FSP1 protein and a consequent increase in the levels of coenzyme Q10, an endogenous lipophilic antioxidant. This suggests that MDM2 and MDMX normally prevent cells from mounting an adequate defense against lipid peroxidation and thereby promote ferroptosis in Colon carcinoma.
References
Ref 1 MDM2 and MDMX promote ferroptosis by PPAR-mediated lipid remodeling. Genes Dev. 2020 Apr 1;34(7-8):526-543. doi: 10.1101/gad.334219.119. Epub 2020 Feb 20.